Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.

被引：0
|
作者：
Foltran, Luisa
Bertola, Manuela
Del Conte, Alessandro
Lo Re, Giovanni
Bestetti, Alessandro
Sandri, Paolo
Saracchini, Silvana
机构：
[1] Gen Hosp, Dept Oncol, Pordenone, Italy
[2] Gen Hosp S Maria Angeli, Dept Oncol, Pordenone, Italy
[3] Santa Maria Angeli Hosp, Pordenone, Italy
[4] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[5] S Maria Angeli, Pasiano Di Pordenone, PN, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11576
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11576
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A REVIEW OF EVEROLIMUS-EXEMESTANE COMBINATION TREATMENT IN METASTATIC BREAST CANCER: A REAL-WORLD CLINICAL EXPERIENCE
    Agarwal, A.
    McNeil, C.
    Beith, J. M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 51 - 51
  • [32] Trastuzumab plus paclitaxel in HER-2 positive metastatic breast cancer: A single institutional experience
    Capobianco, A. M. L.
    Di Leo, P.
    Bochicchio, A. M.
    Coccaro, M.
    Romano, G.
    Tartarone, A.
    Ardito, R.
    Musto, C.
    Barone, M.
    Guarigli, R.
    Di Renzo, N.
    ANNALS OF ONCOLOGY, 2005, 16 : 141 - 142
  • [33] A REVIEW OF EVEROLIMUS-EXEMESTANE COMBINATION TREATMENT IN METASTATIC BREAST CANCER - A REAL-WORLD CLINICAL EXPERIENCE
    Agarwal, Anupriya
    Beith, Jane M.
    McNeil, Catriona
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 135 - 135
  • [34] Efficacy and tolerability of Everolimus-Exemestane combination therapy in metastatic breast cancer patients: experience in Real Life
    Cocciolone, V.
    Cannita, K.
    Tessitore, A.
    Rinaldi, L.
    Irelli, A.
    Dal Mas, A.
    Calvisi, G.
    Bafile, A.
    Alesse, E.
    Ricevuto, E.
    Ficorella, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 24 - 24
  • [35] Long-term responders with metastatic breast cancer (MBC) receiving eribulin: Real life experience.
    Gorbunova, Vera
    Manzyuk, Ludmila
    Kovalenko, Elena
    Bolotina, Larisa
    Semiglazova, Tatiana
    Zhilyaeva, Larisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [37] Combination of liposomal doxorubicine plus gemcitabine in heavily pretreated metastatic breast cancer patients: A single center experience.
    Pablo Fusco, Juan
    Martin Romano, Patricia
    Castanon Alvarez, Eduardo
    Ceniceros, Lucia
    Legaspi, Jairo
    Espinos, Jaime
    Gil-Bazo, Ignacio
    Fernandez-Hidalgo, Oscar
    Aramendia, Jose M.
    Santisteban, Marta
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [39] Epidemiology and clinical profile of breast cancer in central Nepal: A single institutional experience.
    Shakya, Sachin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Everolimus in heavily pre-treated metastatic breast cancer (MBC): Is real (developing) world experience different?
    Bajpai, J.
    Ramaswamy, A.
    Ghosh, J.
    Gulia, S.
    Gupta, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S292 - S292
12345